Generate the differentiation chart between ovarian tcancer. , cervical cancer, endometrial cancer . Very summarized one easy to revise before exam.
Reading File
Finding Sources
Searching PubMed
gynecologic cancer diagnosis
Searching the Web
NCI ovarian cervical endometrial cancer symptoms risk factors diagnosis
Finding Sources
Finding Sources
Finding Sources
Searching the Web
site:cancer.gov cervical cancer symptoms HPV screening ovarian cancer symptoms diagnosis NCI
Quick differentiation chart: Ovarian vs Cervical vs Endometrial cancer
| Feature | Ovarian cancer | Cervical cancer | Endometrial cancer |
|---|---|---|---|
| Site | Ovary / fallopian tube | Cervix | Endometrium, uterine lining |
| Typical age | Usually postmenopausal | Middle age, but can occur earlier | Postmenopausal, around 60 years |
| Main risk factor | BRCA1/2 or family history; also endometriosis | Persistent high-risk HPV infection | Unopposed estrogen: obesity, PCOS, nulliparity, estrogen therapy, tamoxifen |
| Typical presentation | Vague, late: bloating, increasing abdominal size, early satiety, pelvic/abdominal pain | Often asymptomatic early; later postcoital bleeding, irregular bleeding, foul watery/bloody discharge | Postmenopausal bleeding is the classic presentation |
| Spread pattern | Early peritoneal spread: ascites, omental deposits | Local spread to vagina, parametria, bladder/rectum; then lymph nodes | Direct invasion into myometrium, then pelvic/para-aortic nodes |
| Screening | No effective routine screening in average-risk women | Pap smear and/or HPV test | No routine screening; evaluate any postmenopausal bleeding |
| Key initial tests | Pelvic/transvaginal US + CA-125, then imaging and histology | Pap/HPV abnormality -> colposcopy + biopsy | Transvaginal US and endometrial biopsy |
| Tumor marker | CA-125: useful mainly for monitoring, not population screening | No routine tumor marker | No routine tumor marker |
| Prevention | Risk-reducing salpingo-oophorectomy in selected high-risk BRCA carriers; OCPs lower risk | HPV vaccination + screening | Weight control; progestin counters unopposed estrogen |
| Exam clue | “Bloating + ascites + adnexal mass” | “Postcoital bleeding + HPV” | “Postmenopausal bleeding + obesity” |
One-line memory trick
- Ovary: Silent abdomen gets swollen.
- Cervix: HPV causes postcoital bleeding.
- Endometrium: Estrogen causes postmenopausal bleeding.
High-yield warning
Postmenopausal bleeding requires evaluation because it may indicate endometrial or cervical malignancy. CA-125 alone should not be used to screen average-risk women for ovarian cancer. These points are supported by Berek & Novak's Gynecology and Schwartz's Principles of Surgery, and by NCI endometrial cancer guidance, NCI cervical cancer information, and NCI ovarian cancer prevention information.
Make it suitable for Longcase viva
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
gynecologic malignancy diagnosis
Searching the Web
cervical ovarian endometrial cancer diagnosis pelvic examination NCI
Long-case viva differentiation: Ovarian vs Cervical vs Endometrial cancer
| Viva point | Ovarian cancer | Cervical cancer | Endometrial cancer |
|---|---|---|---|
| Usual patient | Older, postmenopausal woman | Reproductive or middle-aged woman | Postmenopausal woman, often obese |
| Main symptom | Abdominal distension, bloating, early satiety, pelvic pain | Postcoital bleeding, intermenstrual bleeding, offensive watery discharge | Postmenopausal bleeding |
| Risk factors to ask | Family history of breast/ovarian cancer, BRCA mutation, nulliparity, endometriosis | Early sexual activity, multiple partners, smoking, immunosuppression, no screening | Obesity, diabetes, hypertension, PCOS, nulliparity, late menopause, tamoxifen, unopposed estrogen, Lynch syndrome |
| Core cause/association | BRCA-related in some patients | Persistent high-risk HPV, especially types 16 and 18 | Prolonged unopposed estrogen exposure |
| Abdominal examination | Ascites, abdominal mass, umbilical nodule, pleural effusion in advanced disease | Usually normal unless advanced disease | Usually normal; may have enlarged uterus or metastases if advanced |
| Speculum examination | Cervix often normal | Visible cervical growth: ulcerative, proliferative or friable lesion that bleeds on touch | Cervix often normal, though blood may be seen coming through the os |
| Bimanual pelvic examination | Adnexal mass: irregular, solid/cystic, fixed; pouch of Douglas nodules | Hard, irregular cervix; parametrial induration/fixity indicates local spread | Uterus may be enlarged; assess cervical involvement and adnexal mass |
| Rectovaginal examination | Nodularity in pouch of Douglas, pelvic sidewall deposits | Essential to assess parametrial involvement, pelvic sidewall fixation and rectal mucosa | Assess parametria, rectovaginal septum and pelvic spread |
| Most useful diagnostic confirmation | Surgical histopathology, usually after imaging assessment | Cervical biopsy after colposcopy | Endometrial biopsy or hysteroscopy-directed biopsy |
| Initial investigation | Transvaginal US + CA-125; CT abdomen/pelvis for extent/resectability | Pap/HPV test may detect precursor lesions; colposcopy and biopsy for diagnosis; MRI pelvis for local extent | Transvaginal US for endometrial thickness, then endometrial sampling |
| Tumor marker | CA-125 for baseline and treatment monitoring. Not diagnostic alone and not for average-risk screening. | No standard tumor marker | No standard tumor marker |
| Spread pattern | Transcoelomic: peritoneum, omentum, ascites, pleura | Direct local extension to vagina, parametria, bladder/rectum, then lymph nodes | Myometrial invasion, cervix, adnexa, pelvic and para-aortic lymph nodes |
| General treatment principle | Cytoreductive surgery plus platinum-based chemotherapy | Early disease: surgery or radiotherapy. Locally advanced: concurrent chemoradiation | Primary surgery: total hysterectomy with bilateral salpingo-oophorectomy, with staging; adjuvant therapy according to risk/stage |
| Prevention / screening | No routine effective screening for average-risk women | HPV vaccination and cervical screening | No routine population screening; promptly investigate postmenopausal bleeding |
How to present it in a viva
If the patient has an abdominal mass with ascites:
“My leading diagnosis is ovarian malignancy, particularly epithelial ovarian cancer. I would look for an irregular fixed adnexal mass, ascites, omental or pouch-of-Douglas nodularity, and metastatic features. I would evaluate with transvaginal ultrasound, CA-125 and contrast CT, with histological confirmation and staging at surgery where appropriate.”
If the patient has postcoital bleeding or a cervical growth:
“My leading diagnosis is carcinoma cervix. On speculum examination I would assess the lesion and obtain or arrange a biopsy. On bimanual and rectovaginal examination, the key staging assessment is parametrial involvement and pelvic sidewall fixation.”
If the patient has postmenopausal bleeding:
“Endometrial carcinoma must be excluded until proven otherwise. I would assess risk factors for unopposed estrogen exposure, perform pelvic examination, arrange transvaginal ultrasound and obtain endometrial tissue for histopathology.”
Examiner's rapid-fire differentiators
- Postcoital bleeding -> think cervical cancer.
- Postmenopausal bleeding -> think endometrial cancer.
- Ascites + adnexal mass + early satiety -> think ovarian cancer.
- HPV -> cervical cancer.
- Obesity and unopposed estrogen -> endometrial cancer.
- BRCA/family history of breast-ovarian cancer -> ovarian cancer.
- Parametrial involvement -> cervical cancer staging.
- CA-125 -> ovarian cancer monitoring, not screening.
- Endometrial biopsy -> confirms endometrial cancer.
- Cervical biopsy -> confirms cervical cancer.
Textbook support: a solid, irregular, fixed pelvic mass and ascites are suggestive of ovarian malignancy; Berek & Novak's Gynecology. Cervical assessment includes speculum, bimanual and nodal examination; Berek & Novak's Gynecology. Postmenopausal bleeding is the typical presentation of endometrial cancer; Schwartz's Principles of Surgery. Current NCI resources also support cervical diagnostic evaluation, endometrial sampling, and the lack of mortality benefit from routine ovarian cancer screening.
This is a shared conversation. Sign in to Orris to start your own chat.